FunPep Company Limited (JP:4881)
:4881
Want to see JP:4881 full AI Analyst Report?
4881 Stock Chart & Stats
¥79.00
¥1.00(0.72%)
At close: 4:00 PM EST
¥79.00
¥1.00(0.72%)
Day’s Range― - ―
52-Week Range¥57.00 - ¥130.00
Previous CloseN/A
Volume532.20K
Average Volume (3M)245.82K
Market Cap
¥3.19B
Enterprise Value¥824.17M
Total Cash (Recent Filing)¥2.33B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.98
Shares Outstanding50,666,700
10 Day Avg. Volume262,310
30 Day Avg. Volume245,823
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.13
Price to Sales (P/S)9943.96
P/FCF Ratio-2.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-34.5
Revenue Forecast (FY)¥500.00M
Bulls Say, Bears Say
Bulls Say
Clean Balance Sheet (zero Debt)Zero total debt materially reduces refinancing and interest-service risk for an early-stage biotech. That structural flexibility preserves optionality for R&D and partnering decisions, allowing management to prioritize clinical progress without near-term debt pressures.
Proprietary Peptide Platform & Immunotherapy FocusA proprietary peptide platform and immunotherapy focus create a durable competitive edge: platform reuse across indications can accelerate program starts, strengthen IP, and underpin long-term licensing or collaboration value as immunotherapy remains a structural industry growth area.
Licensing And Partnership Revenue ModelA business model centered on licensing and partnerships shifts commercialization risk to partners and offers milestone/royalty revenue streams. Structurally this enables capital-efficient pipeline advancement and access to partner resources without taking on debt, aiding long-term program funding.
Bears Say
Severe Revenue Collapse & Widening LossesA ~94% revenue drop and sharply wider net losses indicate fundamental revenue fragility and failing revenue streams. Persistently negative profitability undermines ability to fund clinical development, weakens partner leverage, and signals material execution or product-cycle issues over the medium term.
Accelerating Negative Operating Cash FlowOperating cash flow deterioration signals accelerating cash burn and that the business is not self-funding. Structurally this shortens runway, increases reliance on external financing or dilutive raises, and heightens risk that programs may be delayed or curtailed absent new partner funding.
Eroding Equity And Persistent Negative ReturnsMaterial equity erosion over years reflects repeated losses and capital consumption, reducing the firm's buffer to absorb setbacks. Persistent negative ROE indicates inability to generate shareholder value, complicating future fundraising and increasing long-term dilution risk for existing shareholders.
4881 FAQ
What was FunPep Company Limited’s price range in the past 12 months?
FunPep Company Limited lowest stock price was ¥57.00 and its highest was ¥130.00 in the past 12 months.
What is FunPep Company Limited’s market cap?
FunPep Company Limited’s market cap is ¥3.19B.
When is FunPep Company Limited’s upcoming earnings report date?
FunPep Company Limited’s upcoming earnings report date is Aug 07, 2026 which is in 56 days.
How were FunPep Company Limited’s earnings last quarter?
FunPep Company Limited released its earnings results on May 12, 2026. The company reported -¥7.03 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.03.
Is FunPep Company Limited overvalued?
According to Wall Street analysts FunPep Company Limited’s price is currently Overvalued.
Does FunPep Company Limited pay dividends?
FunPep Company Limited does not currently pay dividends.
What is FunPep Company Limited’s EPS estimate?
FunPep Company Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does FunPep Company Limited have?
FunPep Company Limited has 50,666,700 shares outstanding.
What happened to FunPep Company Limited’s price movement after its last earnings report?
FunPep Company Limited reported an EPS of -¥7.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.429%.
Which hedge fund is a major shareholder of FunPep Company Limited?
Currently, no hedge funds are holding shares in JP:4881
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
FunPep Company Limited
FunPep Company Limited specializes in the discovery and advancement of pharmaceutical drugs, functional cosmetics, and medical devices, leveraging its core technology in functional peptides. The company's development pipeline prominently features SR-0379, a functional peptide designed to address skin ulcers. FunPep is advancing FPP003, an antibody-inducing peptide, which is undergoing Phase II clinical trials for psoriasis in Australia and for ankylosing spondylitis in Japan. Another antibody-inducing peptide, FPP004X, is also in development, targeting pollinosis. Additionally, the company is working on FPP006, a corona peptide vaccine, and FPP005, an antibody-inducing peptide for psoriasis. Established in 2013, FunPep Company Limited operates from its headquarters in Tokyo, Japan.
Technical Analysis
Peptidream
―
NanoCarrier Co., Ltd.
―
Kohjin Bio Co.,Ltd.
―
Linical Co., Ltd.
―
Immuno-Biological Laboratories Co., Ltd.
―